APRI (Aprinoia Therapeutics) Cash Flow from Financing: $16.29 Mil (TTM As of Dec. 2023)

What is Aprinoia Therapeutics Cash Flow from Financing?

Aprinoia Therapeutics APRI Cash Flow from Financing is $16.29 Mil as of Dec. 2023.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Aprinoia Therapeutics paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $1.22 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $1.78 Mil on other financial activities. In all, Aprinoia Therapeutics earned $3.00 Mil on financial activities for the six months ended in Dec. 2023.

Aprinoia Therapeutics (NAS:APRI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Aprinoia Therapeutics's issuance of stock for the six months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Aprinoia Therapeutics's repurchase of stock for the six months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Aprinoia Therapeutics's net issuance of debt for the six months ended in Dec. 2023 was $1.22 Mil. Aprinoia Therapeutics received $1.22 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Aprinoia Therapeutics's net issuance of preferred for the six months ended in Dec. 2023 was $0.00 Mil. Aprinoia Therapeutics paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Aprinoia Therapeutics's cash flow for dividends for the six months ended in Dec. 2023 was $0.00 Mil. Aprinoia Therapeutics received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Aprinoia Therapeutics's other financing for the six months ended in Dec. 2023 was $1.78 Mil. Aprinoia Therapeutics received $1.78 Mil on other financial activities.

Aprinoia Therapeutics Cash Flow from Financing Related Terms

Aprinoia Therapeutics Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Cash Flow from Financing Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash Flow from Financing

31.49

11.35

16.29

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Cash Flow from Financing	0.00	9.00	2.35	13.29	3.00

Aprinoia Therapeutics Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Aprinoia Therapeutics's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	15.708	+	0	+	0	+	0.58
=	16.29

Aprinoia Therapeutics's Cash from Financing for the quarter that ended in Dec. 2023 is:

	Cash Flow from Financing		(Q: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	1.222	+	0	+	0	+	1.779
=	3.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $16.29 Mil.

Frequently Asked Questions Learn more about Cash Flow from Financing →

What does a Cash Flow from Financing of $16.29 Mil mean?

Aprinoia Therapeutics (APRI) has a Cash Flow from Financing of $16.29 Mil as of Dec. 2023. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Aprinoia Therapeutics and its competitors.

Is Aprinoia Therapeutics' Cash Flow from Financing too high?

Aprinoia Therapeutics' current Cash Flow from Financing is $16.29 Mil.

How does Aprinoia Therapeutics' Cash Flow from Financing compare to ?

Aprinoia Therapeutics' Cash Flow from Financing of $16.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash Flow from Financing for a Biotechnology company?

A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash Flow from Financing mean?

A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Cash Flow from Financing is $16.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aprinoia Therapeutics stock overvalued right now?

Aprinoia Therapeutics (APRI) has a current Cash Flow from Financing of $16.29 Mil. The current Cash Flow from Financing is $16.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash Flow from Financing calculated?

Cash Flow from Financing is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Cash Flow from Financing is $16.29 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies

Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142

Website https://www.aprinoia.com

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.